XOMA Royalty Corporation reported its first quarter 2025 financial results, showing a significant increase in total income and revenues, which rose to $15.9 million from $1.5 million in the same period of 2024. The increase was primarily attributed to income from the effective interest rate method related to VABYSMO®, a $4.0 million milestone associated with Day One and Ipsen's MAA filing with the EMA, a $4.0 million payment from a collaboration agreement with Takeda, and $1.5 million in estimated royalties related to OJEMDA™. Net income for the quarter ending March 31, 2025, was $2.4 million, contrasting with a net loss of $8.6 million in the first quarter of 2024. The company also highlighted $18.0 million in cash receipts during the quarter, including $13.4 million from royalty receipts. In terms of business development, XOMA acquired an economic interest in Castle Creek Biosciences' D-Fi (FCX-007) through a syndicated royalty financing transaction and successfully sold all unpartnered Kinnate assets. The company is focused on generating shareholder value through strategic cash deployment, expense control, and share repurchases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.